FDA Approves Foundayo, a Once-Daily Oral GLP-1 Pill for Weight Loss
The FDA approved Foundayo, a once-daily oral GLP-1 tablet, for weight loss on April 7, 2026. The pill, developed by Eli Lilly, offers an alternative to injectable GLP-1 medications like Ozempic and Wegovy, and is expected to make weight-loss treatment more accessible for patients who prefer not to use injections.
The U.S. Food and Drug Administration approved Foundayo, a once-daily oral GLP-1 tablet for weight loss, on April 7, 2026. The drug, developed by Eli Lilly under the generic name orforglipron, is the first oral GLP-1 medication approved specifically for obesity treatment.
GLP-1 receptor agonists have become widely used for weight management, but until now they have been available only as injections. Foundayo gives patients an oral option, which doctors say could improve adherence and expand access to treatment.
The approval follows clinical trial data showing meaningful weight loss in patients who took the pill daily. Lilly has not yet announced a final retail price, but analysts expect it to be competitive with injectable alternatives.
Health experts welcomed the approval but cautioned that medication alone is not sufficient for lasting weight management. Doctors recommend combining GLP-1 therapy with dietary changes, physical activity, and behavioral support.
Some researchers have raised questions about the long-term cardiovascular effects of stopping GLP-1 medications. A study published earlier in 2026 found that patients who discontinued the drugs may lose some of the cardiovascular benefits they had gained.
The FDA approval covers adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related health condition such as high blood pressure or type 2 diabetes.
Foundayo is expected to be available at pharmacies within weeks of the approval. Insurance coverage will vary by plan, and patient assistance programs are expected to be announced by Lilly.
